Redx Pharma PLC (AIM:REDX) said its second wholly-owned molecule has now entered the clinic.
Candidate RXC007, which is being developed to treat fibrosis, will be administered to healthy volunteers to assess its safety and tolerability and also the way it interacts with the body.
Results from the first-in-man study are expected in the first half of next year.
RXC007 is a Rho-associated coiled-coil containing protein kinase 2, or ROCK2 inhibitor with the potential to block the biological signal pathways associated with fibrosis. It is being developed initially to treat idiopathic pulmonary fibrosis.
“This is the company’s first clinical fibrosis programme and means we now have two wholly-owned products in clinical development,” said Redx chief executive, Lisa Anson.
“RXC007 is also the third molecule discovered by the company to enter the clinic, providing significant validation of our in-house medicinal chemistry and drug discovery expertise.
“We believe there is enormous potential for RXC007 to treat multiple fibrotic diseases and we will initially focus on idiopathic pulmonary fibrosis, a severe and life-threatening chronic lung condition with very poor prognosis and limited treatment options.”
Redx’s lead oncology asset, RXC004, is currently in a phase I and is being administered to patients with advanced malignancies.
The drug developer said it plans to report results at a scientific meeting, as well as initiate multiple phase II studies in the second half of this year.